Intranasal delivery: physicochemical and therapeutic aspects.

By Henry R. Costantino, L. Illum, G. Brandt, P. Johnson, S. Quay. International journal of pharmaceutics, 2007

603 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Intranasal drug delivery: how, why and what for? (2009, background): “At the moment, multidrug resistance transporters has already been identified in human nasal respiratory and olfactory mucosa, which may be involved in the transport of a wide variety of hydrophobic and amphiphilic drugs (13).”
Intranasal delivery of biologics to the central nervous system. (2012, background): “5 kDa polypeptide hormone calcitonin has been used for many years to treat postmenopausal osteoporosis); the major disadvantage of the route (Table 1), aside from the challenge of reproducibility, is that limited absorption across the nasal epithelium has restricted its application to particularly p”
Mucoadhesive polymeric platforms for controlled drug delivery. (2009, methodology): “In addition to local effects, the intranasal route of drug administration has also been used to achieve a distal systemic effect [103].”
Intranasal delivery to the central nervous system: mechanisms and experimental considerations. (2010, background): “Subsequently, numerous reports have shown that therapeutics given by the intranasal route are delivered to the CNS and have the potential to treat neurological diseases and disorders.(3,5,6,14) Intranasal administration of insulin, which is currently under investigation for the treatment of Alzheime”